Literature DB >> 16352700

Further characterization of the time-dependent vascular effects of delta9-tetrahydrocannabinol.

Saoirse E O'Sullivan1, David A Kendall, Michael D Randall.   

Abstract

We have previously shown that over time (2 h), the active ingredient of cannabis, Delta(9)-tetrahydrocannabinol (THC), produces peroxisome proliferator-activated receptor (PPAR) gamma-mediated vasorelaxation of conduit arteries. We have now investigated whether incubation with THC affects agonist-stimulated contractile (methoxamine) and endothelium-dependent vasorelaxant (acetylcholine) responses in the rat superior mesenteric artery (G0) and aorta by myography. We have also investigated whether similar responses are observed in isolated resistance (G3) vessels of the mesenteric bed. In both the aorta and G0, incubation with 10 microM THC for 2 h, but not 10 min, significantly attenuated the contractile responses to methoxamine. This effect of THC was abolished in the presence of the enzyme catalase, which breaks down H(2)O(2), and was reduced in the presence of the superoxide dismutase inhibitor diethyldithiocarbamate (DETCA), but it was not PPARgamma-mediated. THC also inhibited calcium influx in a H(2)O(2)-dependent manner. In G0, but not the aorta, incubation with 10 muM THC for 2 h significantly enhanced endothelium-dependent vasorelaxation. This was inhibited by a PPARgamma antagonist, 2-chloro-5-nitro-N-phenylbenzamide (GW9662), catalase, and DETCA, but not by the NO synthase inhibitor N(G)-nitro-L-arginine methyl ester. By contrast, in G3, no time-dependent vasorelaxation of precontracted arteries to THC was observed, and incubation with THC led to potentiation of contractile responses and blunting of vasorelaxation to acetylcholine, which seems to involve inhibition of endothelium-derived hyperpolarizing factor (EDHF) production, and agonist-stimulated production of EDHF. These data demonstrate further the time-dependent vascular actions of THC and also highlight the heterogenous effects of THC in different arterial types.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16352700     DOI: 10.1124/jpet.105.095828

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

1.  Analgesic tolerance to morphine is regulated by PPARγ.

Authors:  Giordano de Guglielmo; Marsida Kallupi; Giulia Scuppa; Serena Stopponi; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 2.  Role of cannabis in cardiovascular disorders.

Authors:  Hemant Goyal; Hamza H Awad; Jalal K Ghali
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 3.  Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.

Authors:  Nephi Stella
Journal:  Glia       Date:  2010-07       Impact factor: 7.452

Review 4.  Molecular Targets of the Phytocannabinoids: A Complex Picture.

Authors:  Paula Morales; Dow P Hurst; Patricia H Reggio
Journal:  Prog Chem Org Nat Prod       Date:  2017

5.  The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α.

Authors:  Eric J Downer; Eileen Clifford; Sylvie Amu; Padraic G Fallon; Paul N Moynagh
Journal:  J Biol Chem       Date:  2012-05-31       Impact factor: 5.157

6.  Behavioral and temperature effects of delta 9-tetrahydrocannabinol in human-relevant doses in rats.

Authors:  Michael S Smirnov; Eugene A Kiyatkin
Journal:  Brain Res       Date:  2008-06-26       Impact factor: 3.252

Review 7.  Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.

Authors:  S E O'Sullivan
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

Review 8.  The therapeutic potential of novel cannabinoid receptors.

Authors:  Faith R Kreitzer; Nephi Stella
Journal:  Pharmacol Ther       Date:  2009-02-25       Impact factor: 12.310

Review 9.  Is the cardiovascular system a therapeutic target for cannabidiol?

Authors:  Christopher P Stanley; William H Hind; Saoirse E O'Sullivan
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 10.  An update on PPAR activation by cannabinoids.

Authors:  Saoirse Elizabeth O'Sullivan
Journal:  Br J Pharmacol       Date:  2016-05-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.